Cocrystal Pharma shares surge 79.90% intraday as CDI-988 receives FDA fast-track designation and Phase 1b trial initiates.

Cocrystal Pharma surged 79.90% intraday, driven by announcements related to its CDI-988 candidate. On April 2, 2026, the company announced that the FDA has granted Fast Track designation to CDI-988, an oral direct-acting protease inhibitor, for the treatment and prevention of norovirus infection—marking it as the first oral antiviral candidate for this use. On March 31, 2026, the company disclosed that the Phase 1b norovirus challenge trial for CDI-988 has commenced at Emory University School of Medicine, evaluating its preventive and therapeutic effects in healthy subjects.